A Phase 3 interventional study of Ramipril in Glomerulonephritis, sponsored by Sanofi. Completed at 1 site in Hong Kong. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-11-18.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy.
149 studies on the registry are indexed under Glomerulonephritis; 38 are open to participants now.
This study's enrollment of 60 is above the median of 40 across 112 interventional studies indexed under Glomerulonephritis.
Browse Glomerulonephritis studies →Sanofi is the lead sponsor of 1,508 studies on the registry; 90 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 118 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Ramipril
Drug: Ramipril
2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
Development of hypertension (defined as blood pressure above 140/90 mm Hg and require anti-hypertensive therapy)
Time frame: From the beginning to the end of the study
Development of proteinuria
Time frame: From the beginning to the end of the study
20% decline in creatinine clearance, as determined by 24-hour urine collection or estimated by the Gault-Cockroft equation
Time frame: From the beginning to the end of the study
body weight, blood pressure, pulse
Time frame: From the beginning to the end of the study
Adverse effects of treatment
Time frame: From the beginning to the end of the study
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi